GSA Capital Partners LLP Reduces Holdings in Natera, Inc. (NASDAQ:NTRA)

GSA Capital Partners LLP lessened its holdings in Natera, Inc. (NASDAQ:NTRA) by 66.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,958 shares of the medical research company’s stock after selling 21,977 shares during the period. GSA Capital Partners LLP’s holdings in Natera were worth $1,391,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of NTRA. Vanguard Group Inc. grew its holdings in Natera by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock valued at $1,010,152,000 after buying an additional 72,848 shares during the last quarter. Farallon Capital Management LLC lifted its position in shares of Natera by 13.6% in the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after acquiring an additional 532,874 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Natera by 6.6% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company’s stock valued at $259,634,000 after acquiring an additional 148,917 shares during the last quarter. Duquesne Family Office LLC boosted its stake in shares of Natera by 2.4% during the second quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock valued at $213,860,000 after acquiring an additional 45,500 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in Natera by 25.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company’s stock valued at $156,092,000 after purchasing an additional 246,246 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Price Performance

NTRA opened at $160.97 on Thursday. The company has a 50 day moving average of $126.04 and a two-hundred day moving average of $114.84. Natera, Inc. has a 52-week low of $49.97 and a 52-week high of $167.79. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The company has a market cap of $19.91 billion, a P/E ratio of -91.46 and a beta of 1.53.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.88% and a negative net margin of 14.01%. The firm had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same period in the prior year, the firm earned ($0.95) EPS. The firm’s quarterly revenue was up 63.9% compared to the same quarter last year. On average, analysts expect that Natera, Inc. will post -1.96 earnings per share for the current year.

Insider Activity at Natera

In other Natera news, Director Rowan E. Chapman sold 2,614 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $127.68, for a total value of $333,755.52. Following the completion of the transaction, the director now owns 7,969 shares in the company, valued at $1,017,481.92. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Steven Leonard Chapman sold 5,024 shares of Natera stock in a transaction on Monday, September 16th. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52. Following the sale, the chief executive officer now owns 195,686 shares of the company’s stock, valued at $25,141,737.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Rowan E. Chapman sold 2,614 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $127.68, for a total transaction of $333,755.52. Following the completion of the transaction, the director now directly owns 7,969 shares of the company’s stock, valued at approximately $1,017,481.92. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,881 shares of company stock worth $3,733,983. 7.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

NTRA has been the topic of several analyst reports. Morgan Stanley raised their price target on shares of Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. Sanford C. Bernstein upped their price objective on shares of Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. TD Cowen lifted their target price on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday. Piper Sandler reiterated an “overweight” rating and issued a $150.00 price target on shares of Natera in a report on Friday, September 13th. Finally, Canaccord Genuity Group lifted their price objective on Natera from $150.00 to $165.00 and gave the company a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $135.06.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.